Sectors & IndustriesHealthcare
Best Healthcare Stocks to Buy Now (2025)
Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

Sector: Healthcare
Ticker
Company
Zen Rating
Sentiment
Market Cap
Shares
Institutional %
Insider %
Net Insider (L12M)
Net Insider (L3M)
EUDA
EUDA HEALTH HOLDINGS LTD
$78.03M37,156,3822.27%26.38%
ONCO
ONCONETIX INC
$5.24M1,545,7040.15%99.85%
ENTX
ENTERA BIO LTD
$132.27M45,452,16722.47%16.68%Net Buying
FBLG
FIBROBIOLOGICS INC
$16.46M41,889,14212.20%14.47%Net Buying
UPC
UNIVERSE PHARMACEUTICALS INC
$2.66M563,3380.00%0.00%
AVDL
AVADEL PHARMACEUTICALS PLC
$1.83B97,097,63983.77%13.63%Net Buying
APRE
APREA THERAPEUTICS INC
$8.16M5,825,2612.97%97.03%Net Buying
OGEN
ORAGENICS INC
$876.90k715,8360.26%99.74%Net Selling
BBLG
BONE BIOLOGICS CORP
$3.82M1,795,2600.01%99.99%
LPTX
LEAP THERAPEUTICS INC
$18.52M41,439,52928.54%71.46%Net Selling
NXTC
NEXTCURE INC
$29.45M2,337,51542.37%57.63%
ZCMD
ZHONGCHAO INC
$17.34M25,388,9030.30%0.00%
SYBX
SYNLOGIC INC
$19.77M11,696,1095.62%94.38%Net SellingNet Selling
ICCC
IMMUCELL CORP
$56.44M9,045,85114.47%21.19%Net Buying
NTRB
NUTRIBAND INC
$80.99M12,034,8832.89%47.44%
PCSA
PROCESSA PHARMACEUTICALS INC
$19.59M50,349,1490.74%8.06%Net Buying
NSYS
NORTECH SYSTEMS INC
$25.70M2,760,9932.60%97.40%Net Buying
NSPR
INSPIREMD INC
$92.20M41,720,66233.70%60.15%Net Buying
ANTX
AN2 THERAPEUTICS INC
$33.61M27,326,16527.38%72.62%Net Selling
ALUR
ALLURION TECHNOLOGIES INC
$14.36M7,762,68125.12%74.88%Net Buying
LFWD
LIFEWARD LTD
$9.71M15,704,6221.40%98.60%Net SellingNet Selling
ADVM
ADVERUM BIOTECHNOLOGIES INC
$90.23M20,984,16130.21%69.79%Net Buying
ESLA
ESTRELLA IMMUNOPHARMA INC
$89.70M37,065,5891.71%80.01%
ALZN
ALZAMEND NEURO INC
$7.94M3,139,8610.01%99.99%Net BuyingNet Buying
NLSP
NLS PHARMACEUTICS LTD
$3.16M4,152,0563.88%0.00%
NSRX
NASUS PHARMA LTD
N/A9,009,9990.00%0.00%
STAA
STAAR SURGICAL CO
$1.28B49,553,03559.70%40.30%Net Buying
NIVF
NEWGENIVF GROUP LTD
$209.71k275,9360.31%99.69%
IBO
IMPACT BIOMEDICAL INC
$6.52M12,185,4123.87%17.31%Net Selling
ASRT
ASSERTIO HOLDINGS INC
$71.60M96,239,62526.03%21.24%Net Selling
TXMD
THERAPEUTICSMD INC
$13.77M11,574,3623.56%96.44%Net Buying
ADVB
ADVANCED BIOMED INC
$10.41M21,640,0000.61%0.00%
MTSR
METSERA INC
$6.62B105,055,53846.71%53.29%Net BuyingNet Selling
AKRO
AKERO THERAPEUTICS INC
$4.32B79,717,57074.85%25.15%Net BuyingNet Buying
BGM
BGM GROUP LTD
$68.36M7,226,4801.83%0.00%
LNSR
LENSAR INC
$145.04M11,792,15638.62%51.31%Net Selling
PMCB
PHARMACYTE BIOTECH INC
$6.32M6,795,7798.49%16.56%
ELUT
ELUTIA INC
$38.54M42,395,34133.50%66.50%Net BuyingNet Selling
AIM
AIM IMMUNOTECH INC
$5.69M2,708,6880.12%99.88%Net Buying
AHG
AKSO HEALTH GROUP
$893.12M1,655,583,5300.01%0.00%
NDRA
ENDRA LIFE SCIENCES INC
$3.95M752,7550.42%99.58%Net BuyingNet Buying
IKT
INHIBIKASE THERAPEUTICS INC
$109.54M74,516,63572.94%27.06%
IMCC
IM CANNABIS CORP
$5.82M4,044,8125.59%0.00%
IRIX
IRIDEX CORP
$17.84M16,992,25312.20%87.80%Net BuyingNet Buying
BRTX
BIORESTORATIVE THERAPIES INC
$12.29M7,978,1170.24%99.76%Net BuyingNet Buying
IMDX
INSIGHT MOLECULAR DIAGNOSTICS INC
$172.00M28,619,74915.71%84.29%Net Buying
POAI
PREDICTIVE ONCOLOGY INC
$6.48M726,1620.08%99.92%
KTTA
PASITHEA THERAPEUTICS CORP
$6.06M7,443,5772.86%97.14%Net Selling
PRPH
PROPHASE LABS INC
$15.12M41,541,2056.45%24.84%
LYRA
LYRA THERAPEUTICS INC
$9.47M1,644,4544.59%95.41%Net Selling
CNSP
CNS PHARMACEUTICALS INC
$4.42M574,58031.08%68.92%
ACON
ACLARION INC
$4.52M582,3710.13%99.87%
COCH
ENVOY MEDICAL INC
$17.32M21,520,93250.10%49.90%Net Buying
CODX
CO-DIAGNOSTICS INC
$17.72M38,523,58213.37%25.74%Net Selling
ADTX
ADITXT INC
$293.62k4,976,5550.78%99.22%
EDSA
EDESA BIOTECH INC
$13.06M7,022,67818.80%81.20%Net Buying
NRXS
NEURAXIS INC
$26.82M9,858,7168.57%25.80%Net Selling
ADAG
ADAGENE INC
$83.89M58,914,08710.30%0.00%
ADIL
ADIAL PHARMACEUTICALS INC
$7.64M21,828,2151.08%21.16%
MYNZ
MAINZ BIOMED NV
$6.06M4,091,8539.42%0.00%
MURA
MURAL ONCOLOGY PLC
$36.21M17,324,35947.52%13.44%Net Selling
EVGN
EVOGENE LTD
$10.98M8,714,2301.50%0.00%
VIVS
VIVOSIM LABS INC
$7.02M2,599,7970.73%99.27%
EVO
EVOTEC SE
$1.45B177,766,5415.43%0.00%
MTVA
METAVIA INC
$24.03M24,197,8090.81%99.19%Net Buying
MBIO
MUSTANG BIO INC
$6.35M4,377,8371.70%17.70%Net Selling
MTNB
MATINAS BIOPHARMA HOLDINGS INC
$7.02M5,086,9850.91%99.09%
ADGM
ADAGIO MEDICAL HOLDINGS INC
$17.53M15,381,56553.92%46.08%
FONR
FONAR CORP
$100.30M6,585,97844.38%3.58%
MBRX
MOLECULIN BIOTECH INC
$14.08M30,286,1681.43%20.90%Net Buying
GDTC
CYTOMED THERAPEUTICS LTD
$25.39M11,540,0000.39%57.45%
GLMD
GALMED PHARMACEUTICALS LTD
$7.27M5,303,0501.43%0.00%
MSPR
MSP RECOVERY INC
$309.52k1,406,9162.30%97.70%Net Selling
MRUS
MERUS NV
$7.17B75,634,35890.68%9.32%Net Buying
HSCS
HEARTSCIENCES INC
$8.08M2,647,7122.28%1.21%Net Selling
SMLR
SEMLER SCIENTIFIC INC
$391.73M14,804,69362.03%37.97%Net BuyingNet Buying
FORA
FORIAN INC
$69.69M31,112,31213.02%60.83%Net BuyingNet Selling
VANI
VIVANI MEDICAL INC
$95.38M59,243,9032.70%97.30%Net BuyingNet Buying
INAB
IN8BIO INC
$8.85M4,539,7173.61%96.39%Net Buying
CYCN
CYCLERION THERAPEUTICS INC
$6.24M3,337,43610.87%85.27%Net Selling
INNV
INNOVAGE HOLDING CORP
$609.01M135,637,9754.60%95.40%Net BuyingNet Selling
MOVE
MOVANO INC
$4.76M834,90817.98%82.02%
MOLN
MOLECULAR PARTNERS AG
$135.88M37,392,3559.59%0.00%
RNTX
REIN THERAPEUTICS INC
$36.47M23,305,10815.54%84.46%Net BuyingNet Buying
MNOV
MEDICINOVA INC
$81.42M49,046,24610.54%89.10%
MLEC
MOOLEC SCIENCE SA
$2.58M4,000,3670.00%86.24%
PIII
P3 HEALTH PARTNERS INC
$63.54M7,187,3420.10%99.90%
SRXH
SRX HEALTH SOLUTIONS INC
$7.46M24,853,6330.47%39.33%Net BuyingNet Buying
MHUA
MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO LTD
$7.43M31,904,4680.52%0.00%
RNA
AVIDITY BIOSCIENCES INC
$8.42B120,538,35988.73%11.27%Net SellingNet Selling
BYSI
BEYONDSPRING INC
$80.26M40,332,32014.88%12.00%Net SellingNet Selling
CUE
CUE BIOPHARMA INC
$59.02M76,845,90422.58%7.36%Net Buying
VTVT
VTV THERAPEUTICS INC
$69.48M3,194,5640.96%99.04%Net BuyingNet Buying
MLSS
MILESTONE SCIENTIFIC INC
$32.99M78,559,1475.96%64.42%Net SellingNet Selling
DYAI
DYADIC INTERNATIONAL INC
$40.89M36,187,7988.67%91.33%Net Buying
WORX
SCWORX CORP
$2.40M7,881,0920.65%36.99%
CLSD
CLEARSIDE BIOMEDICAL INC
$21.30M5,234,02425.51%74.49%Net Buying

Healthcare Industries

IndustryStocks1d %1w %1m %1y %DD ScoreP/E ratioP/B RatioROEROAROCEUpside/DownsideConsensus
624+0.64%+2.90%+9.49%-20.20%-9.17x4.99x-99.14%-9.57%-19.67%+59.31%Strong Buy
56+1.98%-1.71%+10.79%+11.83%22.03x4.25x-3.47%+6.92%+14.45%+3.99%Strong Buy
20+0.87%+1.10%+5.98%+2.01%35.14x6.26x+64.80%+11.73%+19.54%+8.05%Buy
77+0.70%-0.39%-0.78%-18.68%-14.62x2.21x+10.48%+4.13%+9.69%+35.70%Strong Buy
10-0.97%-8.09%-4.64%-26.28%43.12x2.05x+12.53%+3.88%+9.46%+21.30%Buy
55+1.29%-1.59%+3.39%-53.33%64.86x4.57x-39.80%-0.81%+3.43%+23.56%Strong Buy
49-1.87%-1.42%+0.29%-25.38%16.45x5.25x-80.81%+7.16%+16.38%+16.85%Buy
139-0.05%-3.15%-0.54%-34.28%27.18x3.86x+11.53%+7.88%+9.81%+29.98%Strong Buy
11-1.21%+2.91%+6.98%+50.46%31.55x556.06x-11.84%+3.12%+19.04%+5.23%Buy
56+0.19%-3.98%+1.60%-54.92%37.95x3.55x+11.04%+9.00%+12.26%+22.92%Buy

Healthcare Stocks FAQ

What are the best healthcare stocks to buy right now in Nov 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

1. Amneal Pharmaceuticals (NASDAQ:AMRX)


Amneal Pharmaceuticals (NASDAQ:AMRX) is the #1 top healthcare stock out of 1097 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: B.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 31, which is 6 points higher than the healthcare sector average of 25. It passed 10 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 27.74% over the past year, overperforming other healthcare stocks by 51 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $13.50, an upside of 24.77% from Amneal Pharmaceuticals's current stock price of $10.82.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Ironwood Pharmaceuticals (NASDAQ:IRWD)


Ironwood Pharmaceuticals (NASDAQ:IRWD) is the #2 top healthcare stock out of 1097 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ironwood Pharmaceuticals (NASDAQ:IRWD) is: Value: A, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: A.

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a Due Diligence Score of 3, which is -22 points lower than the healthcare sector average of 25. Although this number is below the industry average, our proven quant model rates IRWD as a "A".It passed 1 out of 33 due diligence checks and has weak fundamentals. Ironwood Pharmaceuticals has seen its stock lose -51.39% over the past year, underperforming other healthcare stocks by -28 percentage points.

3. Embecta (NASDAQ:EMBC)


Embecta (NASDAQ:EMBC) is the #3 top healthcare stock out of 1097 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: B.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 10 points higher than the healthcare sector average of 25. It passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -5.26% over the past year, overperforming other healthcare stocks by 18 percentage points.

Embecta has an average 1 year price target of $18.50, an upside of 38.68% from Embecta's current stock price of $13.34.

Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the healthcare stocks with highest dividends?

Out of 70 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

1. Select Medical Holdings (NYSE:SEM)


Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 13.3%, which is 11 percentage points higher than the healthcare sector average of 2.18%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 36% indicates that its high dividend yield is sustainable for the long-term.

2. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 10.57%, which is 8 percentage points higher than the healthcare sector average of 2.18%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

3. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) has an annual dividend yield of 8.89%, which is 7 percentage points higher than the healthcare sector average of 2.18%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.7% indicates that its high dividend yield is sustainable for the long-term.

Why are healthcare stocks up?

Healthcare stocks were up 0.47% in the last day, and down -0.37% over the last week. Cabaletta Bio was the among the top gainers in the healthcare sector, gaining 46.15% yesterday.

Cabaletta Bio shares are trading higher after Cantor Fitzgerald maintained its overweight on the stock and raised Its price target from $15 to $30.

What are the most undervalued healthcare stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 54 points higher than the healthcare sector average of 17. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -11.08% in the past year. It has overperformed other stocks in the healthcare sector by 12 percentage points.

2. Bausch Health Companies (NYSE:BHC)


Bausch Health Companies (NYSE:BHC) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Bausch Health Companies's stock has dropped -23.7% in the past year. It has underperformed other stocks in the healthcare sector by -1 percentage points.

3. Auna Sa (NYSE:AUNA)


Auna Sa (NYSE:AUNA) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Auna Sa has a valuation score of 57, which is 40 points higher than the healthcare sector average of 17. It passed 4 out of 7 valuation due diligence checks.

Auna Sa's stock has dropped -12.57% in the past year. It has overperformed other stocks in the healthcare sector by 11 percentage points.

Are healthcare stocks a good buy now?

54.42% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 31.16% over the next year.

6.16% of healthcare stocks have a Zen Rating of A (Strong Buy), 11.85% of healthcare stocks are rated B (Buy), 47.27% are rated C (Hold), 25.09% are rated D (Sell), and 9.64% are rated F (Strong Sell).

What is the average p/e ratio of the healthcare sector?

The average P/E ratio of the healthcare sector is 25.1x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.